Details of the Drug

General Information of Drug (ID: DM3XU74)

Drug Name
Dornase Alfa
Synonyms Pulmozyme (TN)
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [2]
Therapeutic Class
Enzyme Replacement Agents
Affected Organisms
Humans and other mammals
Sequence
LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP
DTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS
RFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ
WSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG
LSDQLAQAISDHYPVEVMLK
ADMET Property
Metabolism
The drug is metabolized via proteases in biofluids []
Cross-matching ID
UNII
953A26OA1Y
DrugBank ID
DB00003
TTD ID
D0JE4D
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 ClinicalTrials.gov (NCT04359654) Nebulised Dornase Alfa for Treatment of COVID-19. U.S. National Institutes of Health.
3 Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45.